Recent studies indicate that advanced imaging parameters such as PSMA-derived tumor volume (PSMA-TV), total lesion PSMA (TL-PSMA), and PSMA total lesion quotient (PSMA-TLQ) measured using PSMA-PET/CT have a promising potential role in the assessment and treatment response prediction in castration-resistant prostate cancer patients [18,19]. The gene discussed is FOLH1; the disease is Familial prostate cancer.